This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.
Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017
(in million U.S. dollars)
This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA). Values are inflation adjusted for 2017 U.S. dollars.
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Single Account
Your perfect start with Statista
Instant access to 1m statistics
Download in XLS, PDF & PNG format
Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Statista Accounts:
Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
JAMA. (November 1, 2017). Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars) [Graph]. In Statista. Retrieved February 27, 2020, from https://www.statista.com/statistics/788904/randd-costs-for-select-cancer-drugs-including-capital/
JAMA. "Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)." Chart. November 1, 2017. Statista. Accessed February 27, 2020. https://www.statista.com/statistics/788904/randd-costs-for-select-cancer-drugs-including-capital/
JAMA. (2017). Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars). Statista. Statista Inc.. Accessed: February 27, 2020. https://www.statista.com/statistics/788904/randd-costs-for-select-cancer-drugs-including-capital/
JAMA. "Total R&d Costs including 7 Percent Annual Cost of Capital for Select Cancer Drugs on The Market as of 2017 (in Million U.S. Dollars)." Statista, Statista Inc., 1 Nov 2017, https://www.statista.com/statistics/788904/randd-costs-for-select-cancer-drugs-including-capital/
JAMA, Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars) Statista, https://www.statista.com/statistics/788904/randd-costs-for-select-cancer-drugs-including-capital/ (last visited February 27, 2020)
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.
